David Toung

Senior Analyst: Medical Devices & Healthcare Services,

Argus Research Corporation

About David

David Toung covers the pharmaceutical, medical devices, and healthcare services sectors for Argus. He has more than two decades of experience in the financial analysis industry, having worked for McDonald & Co., JPMorgan Chase, and Standard & Poor's, among others. His commentary has appeared on CNBC and in The New York Times. Prior to his financial career, Mr. Toung was a private practice attorney in New Jersey and served as a Judicial Clerk for an Appellate Division judge in the New Jersey Superior Court. He has a law degree from Rutgers University, where he was a member of the Law Review. Mr. Toung has a BA degree in government from Cornell University. He has passed Level II of the chartered financial analyst examination.

David's Articles

We are reaffirming our "buy" rating on Bio-Techne Corp. (TECH); we are encouraged by the company’s strong performance in fiscal 4Q21, notes David Toung, a healthcare sector analyst with Argus Research, a leading independent Wall Street research firm.
We are reaffirming our "buy" rating on Medtronic plc (MDT) — one of the world’s largest medical technology and solutions companies, notes David Toung, an analyst with Argus Research, a leading independent Wall Street research firm.
We are reiterating our "buy" rating on Catalent (CTLT), a manufacturing and development partner for biotech and pharmaceutical companies, asserts David Toung, an analyst with Argus Research, a leading independent Wall Street research firm.
We are launching coverage of Catalent Inc. (CTLT), a manufacturing and development partner for biotech and pharmaceutical companies, with a "buy" rating, explains David Toung, an analyst at Argus Research, a leading independent Wall Street research firm. 
I